FERENTIS

Their core work

FERENTIS is a Lithuanian biotech SME specializing in biomimetic tissue matrix products — engineered scaffolds that mimic the biological extracellular matrix for cell culture and tissue engineering applications. Their commercial work, validated through the EU SME Instrument, focuses on bringing biomimetic materials to market as research and biomedical tools. Alongside this commercial track, the company engaged in fundamental science through an MSCA-RISE network studying how cell membrane asymmetry and curvature govern membrane protein behavior — providing the molecular-level biology knowledge that informs their product design. They operate at the boundary between materials science, cell biology, and biomedical product development.

What they specialise in

How they've shifted over time

FERENTIS entered H2020 in 2015 with a commercial focus — BIOTIMA was a market validation exercise for a specific product, not basic research. By 2016 they joined assymcurv, an MSCA-RISE mobility network centered on fundamental cell membrane science, suggesting a deliberate move to deepen the scientific base behind their commercial offering. With no keyword data available and only two projects spanning 2015–2019, the trajectory is indicative rather than conclusive, but the pattern — commercial validation first, then scientific depth — is consistent with a young biotech SME investing in IP and credibility.

FERENTIS appears to be building scientific depth alongside commercial ambition — a pattern typical of biotech SMEs preparing for later-stage product development or licensing; future collaborations are likely to sit at the biomedical materials and cell biology interface.

How they like to work

FERENTIS has acted as both coordinator (BIOTIMA) and participant (assymcurv), showing comfort in either role despite being a small SME. With 8 unique partners across 7 countries in only 2 projects, their network density is high relative to project volume, pointing to broad international engagement rather than a tight inner circle. This suggests they are comfortable joining diverse consortia and can take a leadership role when the project is close to their core commercial interest.

Eight unique partners across seven countries from just two projects indicates strong international reach for a micro-SME; the MSCA-RISE format of assymcurv accounts for much of this breadth, as that scheme inherently involves multi-country researcher exchange. No geographic concentration is discernible from the available data.

What sets them apart

FERENTIS is one of very few Baltic SMEs operating at the intersection of biomimetic materials and cell membrane science — a combination that is difficult to find in a single small company. Their SME Instrument track record signals that they have a concrete, market-validated product rather than just research capability, which makes them a more commercially useful partner than a typical academic lab working on similar topics. For consortia building projects in tissue engineering, organ-on-chip, or lipid membrane research, FERENTIS offers both scientific credibility and a commercialization perspective from within the same organization.

Highlights from their portfolio

• BIOTIMA
  Coordinated as a solo SME under the competitive SME Instrument Phase 1, confirming they had a market-ready product concept in biomimetic tissue matrices — a rare achievement for a small Lithuanian company.
• assymcurv
  Participation in an MSCA-RISE network on cell membrane asymmetry and curvature places FERENTIS inside a high-level biophysics research community, providing scientific depth well beyond typical commercial SME involvement.